60 Degrees Pharmaceuticals (SXTP) averts Nasdaq delisting as bid price recovers

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). Nasdaq’s Listing Qualifications Staff confirmed the company now meets all Nasdaq Capital Market listing standards.

The company had previously received a delisting notice after its stock traded below $1.00 for 30 consecutive business days and paid a $20,000 hearing fee to appeal. With compliance restored, the February 19, 2026 Nasdaq Hearings Panel session has been cancelled, the delisting matter is closed, and the company’s common stock and warrants will continue to trade on The Nasdaq Capital Market.

Positive

• Nasdaq compliance restored and delisting averted: The company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the delisting proceeding has been closed, and its common stock and warrants will continue trading on The Nasdaq Capital Market, avoiding the disruption and potential valuation impact of a downgrade to a non-Nasdaq venue.

Negative

• None.

Insights

Capital markets and listing standards analyst

Regaining Nasdaq compliance removes immediate delisting risk and stabilizes SXTP’s market listing.

60 Degrees Pharmaceuticals previously faced a Nasdaq delisting determination after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days under Listing Rule 5550(a)(2). The company appealed and paid a $20,000 hearing fee to stay suspension.

On February 11, 2026, Nasdaq staff notified the company that it has regained compliance with the minimum bid price requirement and is again in good standing with Nasdaq Capital Market listing standards. The scheduled February 19, 2026 hearing was cancelled and the delisting matter closed.

The common stock and warrants will continue trading on The Nasdaq Capital Market, which helps preserve liquidity and institutional access compared with a potential move to an over-the-counter venue. Future company filings may provide more detail on how the share price performance is sustained relative to listing rules.

false 0001946563 DC 0001946563 2026-02-11 2026-02-11 0001946563 SXTP:CommonStockParValue0.0001Member 2026-02-11 2026-02-11 0001946563 SXTP:WarrantsEachWarrantToPurchaseMember 2026-02-11 2026-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 11, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SXTP		The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock		SXTPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

As previously disclosed, on January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. As disclosed in the Notice, Nasdaq staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2). The Company had paid the $20,000 for the hearing fee and requested an appeal with Nasdaq, pursuant to the Notice, which stayed the suspension of trading and the filing of the Form 25-NSE pending the Panel’s decision. 

On February 11, 2026, the Company was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements.

As a result, the hearing before the Nasdaq Hearings Panel that had been scheduled for February 19, 2026, has been cancelled, and this matter is now closed. The Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market.

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.
Date: February 12, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

2

FAQ

What did 60 Degrees Pharmaceuticals (SXTP) announce in this 8-K filing?

60 Degrees Pharmaceuticals announced it has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq staff confirmed the company now meets Nasdaq Capital Market listing standards, closing the prior delisting process and allowing its common stock and warrants to continue trading on Nasdaq.

Why was 60 Degrees Pharmaceuticals (SXTP) at risk of Nasdaq delisting?

SXTP was at risk of delisting because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Nasdaq staff then issued a written notice indicating an intention to delist the company’s common stock and warrants.

How did 60 Degrees Pharmaceuticals respond to Nasdaq’s delisting notice?

The company requested an appeal and paid a $20,000 hearing fee, which stayed trading suspension and the filing of a Form 25-NSE. This appeal process paused the delisting while a Nasdaq Hearings Panel reviewed the matter and allowed SXTP time to regain compliance with the bid price requirement.

How did 60 Degrees Pharmaceuticals regain Nasdaq listing compliance?

Nasdaq’s Listing Qualifications Staff notified the company on February 11, 2026 that it had regained compliance with the minimum $1.00 bid price requirement. This confirmation means SXTP once again meets all Nasdaq Capital Market listing criteria for its common stock and warrants.

What happened to the scheduled Nasdaq hearing for 60 Degrees Pharmaceuticals?

Because SXTP regained compliance, the Nasdaq Hearings Panel session that had been scheduled for February 19, 2026 was cancelled. Nasdaq deemed the delisting matter closed, so no further hearing was necessary and the company’s securities remain listed on The Nasdaq Capital Market.

Will 60 Degrees Pharmaceuticals’ stock and warrants remain on Nasdaq after this filing?

Yes. Following Nasdaq’s confirmation of compliance, the company stated its common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market. This maintains access to a national exchange, which typically supports trading liquidity and broader investor participation.

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.7 KB
• EX-101 XBRL DEFINITION FILE 26.0 KB
• EX-101 XBRL LABEL FILE 35.7 KB
• EX-101 XBRL PRESENTATION FILE 24.6 KB